{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-038593","form_type":"8-K","ticker":"ANRO","cik":"0001999480","company_name":"Alto Neuroscience, Inc.","filed_at":"2026-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.365924+00:00","generated_at":"2026-05-15T08:02:35.830781+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Alto Neuroscience Phase 2 miss for ALTO-101; shifts focus to ALTO-207","bullets":["ALTO-101 did not meet primary EEG or cognitive endpoints in Phase 2 CIAS study.","Near-significant theta-ITC effect (p=0.052); nominal in cognitively impaired subgroup (p=0.03).","Company developed modified-release ALTO-101 formulation; will pursue partnerships, not further internal development.","ALTO-207 Phase 2b in treatment-resistant depression on track for 1H 2026; cash position $275M.","Tolerability favorable with nausea/vomiting in line with placebo; high skin reaction rates observed."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-038593","json":"https://secwatch.observer/filing/0001104659-26-038593.json","markdown":"https://secwatch.observer/filing/0001104659-26-038593.md","text":"https://secwatch.observer/filing/0001104659-26-038593.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1999480/000110465926038593/0001104659-26-038593-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1999480/000110465926038593/tm2610746d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:02:35.830781+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}